search
Back to results

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Primary Purpose

Alzheimer Disease

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
bapineuzumab
placebo
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer Disease focused on measuring antibody, immunotherapy

Eligibility Criteria

50 Years - 88 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD
  • Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
  • Caregiver will participate and be able to attend clinic visits with patient.

Exclusion Criteria:

  • Significant neurological disease other than AD, or a major psychiatric disorder
  • Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
  • Woman of childbearing potential

Sites / Locations

  • Center for Psychiatric Medicine
  • Participant and Clinical Interactions Resources
  • UAB Clinical Research Pharmacy-Russell Clinic
  • University of Alabama-Birmingham
  • Dedicated Clinical Research
  • Banner Alzheimer's Institute
  • Jeffrey S. Gitt, DO, PC
  • The Compounding Center
  • HOPE Research Institute
  • Clinical Trials, Inc.
  • AC Institute, Incorporated
  • Collaborative Neuroscience Network, Inc
  • San Francisco Clinical Research Center
  • Alpine Clinical Research Center, Inc.
  • Associated Neurologists, PC
  • Mile HIgh Research Center
  • Associated Neurologists of Southern Connecticut, P.C.
  • Bendheim Cancer Center
  • Center for Healthy Aging
  • Alzheimer's Disease Research Unit
  • Hospital Research Unit
  • Investigational Drug Service
  • Moshe Hasbani, MD
  • Norman S. Werdiger, MD
  • MR Research Center
  • Yale PET Center
  • Research Center for Clinical Studies, Inc.
  • JEM Research Institute, LLC
  • JEM Research Institute
  • Medical Specialist of the Palm Beaches
  • Brain Matters Research
  • Compass Research, LLC
  • Palm Beach Neurological Center
  • Neurostudies Inc
  • Roskamp Institute
  • University of South Florida
  • Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC
  • Neurostudies.net
  • NeuroStudies.net
  • Alexian Brothers Medical Center
  • Southern Illinois University School of Medicine Department
  • Memorial Medical Center
  • University of Kansas Medical Center
  • Lake Charles Clinical Trials
  • Massachusetts General Hospital
  • Massachusetts General Hosptial
  • Brigham & Womens Hospital
  • Brigham and Women's Hospital
  • Boston Univeristy ADCRP
  • General Clincial Research Center (Infusion Location)
  • IDS Pharmacy (Drug Receipt). Attn:Hyesson Hong
  • Shields MRI
  • Neuroscience Research of the Berkshires
  • Springfield Neurology Associates, LLC
  • University of Michigan Health System
  • University of Michigan Hospital and Health System
  • University of Michigan Health System
  • University of Michigan Health System
  • Michigan State University
  • Hattiesburg Clinic
  • The Center for Pharmaceutical Research P.C.
  • Memory Enhancement Center of America, Inc.
  • Pharmcare USA
  • Alzheimer's Research Corp./Merician Institute for Aging
  • Neurological Care of Central New York
  • Carolina Neuropsychological Services, Inc
  • Healthsouth Blue Ridge Surgery Center
  • Raleigh Neurology Associates
  • Wake Radiology Associates
  • Ohio State University Imaging@Martha Moorehouse
  • The Ohio State University
  • The Ohio State University
  • Summit Research Network(Oregon) Inc.
  • Providence Brain Institute
  • Providence Cognitive Assessment Clinic
  • Providence St. Vincent Medical Center
  • Dr. Michael Gabe (Clinic)
  • Abington Memorial Hosptial
  • Abington Neurological Associates
  • Abington Neurological Assoc
  • Andorra MRI of Flourtown
  • The Clinical Trial Center, LLC
  • Hospital of the University of Pennsylvania
  • Investigational New Drug Services
  • University of Pennsylvania-Penn Memory Center
  • UPENN Clinical and Transitional Research Center
  • Jefferson Hospital for Neuroscience
  • Thomas Jefferson University Hospital
  • Abington Neurological Associates
  • Rhode Island Mood and Memory Research Institute
  • Simpson's Pharmacy
  • Butler Hospital
  • Medical University of South Carolina Hospitals and Clinics
  • Medical University of South Carolina
  • MUSC
  • Medical University of South Carolina
  • Texas Neurology, P.A.
  • Innovative Clinical Trials
  • Integra Clinical Research
  • Integra Clinical Research, LLC
  • Integra Clinical Research
  • Vista Infusions
  • Inventive Infusion Solutions
  • Inventive Infusions Solutions
  • The Memory Clinic
  • The Pharmacy
  • Waisman Center (PET only)
  • University of Wisconsin School of Medicine and Public Health
  • Wm S. Middleton Memorial Veterans Hospital
  • University of Wisconsin Hospitals and Clinics
  • University of Wisconsin School of Medicine and Public Health
  • Instituto Medico Congreso
  • Cemic University Hospital
  • Hospital Italiano de Buenos Aires
  • Instituto Kremer
  • Gosford Hospital; Pharmacy Dept
  • Gosford Hospital
  • Hornsby Kuringai Hospital
  • Royal Adelaide Hospital
  • The Queen Elizabeth Hospital
  • CDAMS Ballarat Base Hospital
  • Heidelberg Repatriation Hospital
  • Hollywood Hospital; Pharmacy Dept
  • McCusker Alzheimer's Research Foundation, Inc.
  • Medizinische Universitaet Graz
  • Landeskrankenhaus Klagenfurt
  • Allg. Krankenhaus der Stadt Wien
  • SZ Sued - Kaiser-Franz-Josef-Spital
  • Donauspital
  • ZNA Middelheim
  • Az. St. Jan Ruddershove 35
  • Cliniques Universitaires St Luc
  • Universitair Ziekenhuis Antwerpen
  • Universitair Ziekenhuis Gasthuisberg
  • H.-Hartziekenhuis Roeselare-Menen
  • Psicomedica Research Group
  • Especialidades Medicas LyS
  • University Hospital Center Zagreb
  • Ita-Suomen Yliopisto
  • University of Turku / CRST
  • CHU Pellegrin
  • Hopital neurologique du Pr A. Vighetto
  • Centre d'Imagerie medicale de Basse Normandie
  • CHU de Caen
  • Hôpitaux Civils de Colmar
  • CHU de Dijon
  • CHRU de Lille
  • Hôpital la Timone
  • CHU Hôpital Gui de Chaulliac
  • CHU Nord - Hôpital Guillaume et René Laënnec
  • Hôpital Cimiez C.M.R.R.
  • Service d'Imagerie Medicale
  • Groupe Hospitalier Broca-La Rochefoucauld
  • Hôpital Pitié-Salpétrière
  • Hospital Jean Bernard CIC
  • C.H.U de Reims
  • CHU de Rennes
  • CHU - Hopital Charles Nicolle
  • Hôpital Purpan
  • CHU Toulouse - Site Casselardit
  • Charite-Universitätsmedizin Berlin
  • St. Josef-Klinikum
  • Universitaetsklinikum Dresden
  • Klinikum der Albert-Ludwigs-Universitaet Freiburg
  • Ortenau Klinikum Offenburg
  • Universitaetsklinikum Ulm
  • A.O. Umberto I
  • Sezione di Neurologia - Dipartimento di Neuroscienze
  • Clinica Neurologica - II Neurologia
  • Dipartimento di Neuroscienze,
  • Unita' Operativa Complessa di Neurologia
  • CeSI (Centro di Scienze dell'invecchiamento) -
  • Fondazione IRCCS- Istituto Neurologico Carlo Besta
  • Ospedale S. Gerardo
  • Clinica Neurologica
  • Unita' Operativa C - Riabilitazione Neurologica
  • Universita degli Studi di Siena
  • Nagoya City University Hospital
  • National Hospital Organization Tokyo National Hospital
  • Yachiyo Hospital
  • Kashiwado Hospital
  • National Hospital Organization Chiba-East Hospital
  • Nippon Medical School Chiba Hokusoh Hospital
  • National Hospital Organization Kokura Medical Center
  • Maebashi Red Cross Hospital
  • Gunma University Hospital
  • Shinozuka Hospital
  • National Hospital Organization Hiroshima-nishi Medical Ctr.
  • Kobe University Hospital
  • Nishi-Kobe Medical Center
  • Kobe City Hospital Org Kobe City Medical Cente West Hp
  • Iwate Medical University Hospital
  • Kagawa University Hospital
  • Nippon Medical School Musashi Kosugi Hospital
  • Yokohama City University Medical Center
  • Shonan Atsugi Hospital
  • Rakuwakai Otowa Hospital
  • National Hospital Organization Minami-Kyoto Hospital
  • National Hospital Organization Maizuru Medical Center
  • National Hospital Organization Matsumoto Medical Center
  • National Hospital Organization Niigata National Hospital
  • Okayama University Hospital
  • National Hospital Organization Minami-Okayama Medical Center
  • Osaka City University Hospital
  • Osaka University Hospital
  • Kansai Medical University Takii Hospital
  • National HP.Org.Shizuoka Inst.Epilepsy,Neurological Disorder
  • Juntendo University Hospital
  • Juntendo Tokyo Koto Geriatric Medical Center
  • Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp
  • Tokyo Medical University Hospital
  • Tokyo Medical University Hachioji Medical Center
  • OCA Hospital
  • Instituto Biomedico de Investigacion A.C
  • Amphia Ziekenhuis
  • Tergooi Ziekenhuizen
  • Kennemer Gasthuis
  • Jeroen Bosch Ziekenhuis
  • Medisch Centrum Alkmaar
  • Vrije Universiteit Medisch Centrum
  • Catharina Ziekenhuis
  • Medisch Centrum Leeuwarden
  • Erasmus MC
  • The Memory Clinic
  • Signet Research
  • NZOZ Dom Suer Ryder, Pallmed Sp. z o.o.
  • Szpital Uniwersytecki, Oddzial Kliniczny Klinik Chorob Wewnetrznych i
  • NZOZ "NEURO-KARD" "ILKOWSKI I PARTNERZY" Spolka Partnerska Lekarzy
  • Oddzial Neurologiczny i Udarowy Szpital Wolski im. dr Anny Gostynskiej,
  • Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika
  • Hospital Fernando da Fonseca
  • Hospitais Da Universidade De Coimbra
  • Hospital Santa Maria
  • Klinicki centar Srbije
  • Clinical Centre Kragujevac, Clinic of Psichiatry
  • Klinicki Centar Vojvodina
  • Diagnostic Imaging Center
  • Institute for Cardiovascular Diseases of Vojvodina
  • Psychiatricka ambulancia
  • Univerzitna nemocnica Bratislava
  • Psychiatricka nemocnica Michalovce, n.o.
  • Vseobecna nemocnica Rimavska Sobota
  • Boithuso Caregivers
  • The Osteoporosis and Memory Centre
  • Denmar Clinic
  • St Augustine's Medical Centre 2
  • Flexivest Fourteen Research Center
  • Panorama Psychiatry and Memory Clinic
  • Hospital General Universitario de Elche
  • Hospital Mutua de Terrassa
  • Hospital Virgen del Puerto
  • Hospital Universitario Son Espases
  • CLONUS
  • Hospital de Donostia
  • Hospital de Cruces
  • Hospital del Mar
  • Fundacio ACE Institut Catala de Neurociences Aplicades
  • Centro Internacional de Medicina Avanzda (CIMA)
  • Hospital de la Santa Creu i Sant Pau
  • Hospital Divino Valles
  • Hospital de la Princesa
  • Hospital Universitario Ramon y Cajal
  • Hospital Clinico San Carlos
  • Hospital 12 de Octubre
  • Hospital Universitario La Paz
  • Hospital Universitario Virgen de la Arrixaca
  • Malmo University Hospital
  • Uppsala Imanet AB
  • Akademiska Sjukhuset
  • ORKI, enheten for radiologi
  • Memory Clinic Neuro-Psychologie Zentrum
  • Hopitaux Universitaires de Geneve
  • CHUV Lausanne
  • Hopitaux Universitaires de Geneve
  • MAC UK Neuroscience Ltd
  • MAC UK Neuroscience, Research Assessment Centre
  • Pollard Park Health Centre
  • Clinical Investigation and Research Unit (CIRU)
  • Glasgow Memory Clinic
  • Kings College Hospital
  • Dept. of Neurosciences Charing Cross Hospital
  • Newcastle General Hospital
  • Northampton General Hospital
  • Llandough Hospital
  • Royal Hallamshire Hospital
  • Grenoside Grange Hospital
  • Victoria Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Bapineuzumab 0.5 mg/kg

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78
The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement.

Secondary Outcome Measures

Change From Baseline in Brain Amyloid Burden at Week 71
Brain amyloid burden as imaged by 11C-Pittsburgh compound B (PIB) positron emission tomography (PET). The latter is a semi-quantitative measure of the extent of fibrillar amyloid in the brain. PIB PET measurements were made in cortical regions found to have the highest burden of fibrillar amyloid at autopsy in participants diagnosed as having Alzheimer's pathology, and also regions reported to have the highest average retention of PIB signal in previous PET studies enrolling participants with probable AD. This parameter reflects overall brain amyloid deposition as indexed by imaging. The change from baseline was measured as average standard uptake value ratio (SUVr) in prespecified regions of interest (ROI) assessed by PIB PET imaging in a subset of participants.
Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71
Biomarkers CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. An elevation in levels of tau, as well as specific p-tau species, is thought to be a marker for progressive cellular degeneration in AD. Accordingly, a reduction from baseline in levels of CSF tau in participants who received bapineuzumab compared with participants who received placebo may be indicative of a reduction in neuronal loss in participants treated with bapineuzumab.
Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71
Cerebral atrophy correlates closely with the gradual cognitive decline in AD and can be visualized by MRI. The BBSI technique involves positional matching of serial 3-dimensional MRI brain images, such that brain MRI-image volumes were first registered and then subtracted from each other. Atrophy rates would generally be expected to be lower if the underlying disease was attenuated by effective treatment.
Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78
Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. ADAS-Cog/11 total score range is 0 (least impairment) to 70 (most impairment); a negative treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Divergence of Effect on the DAD Total Scores From Week 39 to Week 78
Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. DAD total score range is 0 to 100; a positive treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)
The time to first median placebo deterioration, defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score greater than or equal to the median worsening observed at Week 78 in the placebo group. The Kaplan Meier estimate of median time to first median placebo deterioration was presented.
Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)
The time to first clinically meaningful deterioration was defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score of >=7.
Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan)
The time to first median placebo deterioration was defined as the first time a participant experienced a decrease (worsening) in DAD total score greater than or equal to the median worsening at Week 78 in the placebo group.
Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis)
The time to first clinically meaningful deterioration was defined as the first time a participant experienced a decrease (worsening) from baseline in DAD total score of >=12.
Change From Baseline in Dependence Scale Total Score at Week 78
The Dependence Scale (DS) is a 13-item, caregiver-rated instrument for determining the amount of support required by a participant with AD. The DS total score ranges from 0 to 15, with higher scores indicating more need for assistance. The DS was administered as an interview to the caregiver at scheduled study visits.
Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan)
Percentage of participants with worsening from baseline to Week 78 in ADAS-Cog/11 total score of ≤0, ≤3, and ≤7 points were reported. In order to calculate time to first median placebo deterioration in ADAS-Cog/11, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the ADAS-Cog/11 total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the ADAS-Cog/11 total score of 7 points or more and the worsening is confirmed by the ADAS-Cog/11 assessment at the next non-missing visit.
Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)
Percentage of participants whose increase (worsening) from baseline to Week 78 in ADAS-Cog/11 total score was <7.
Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan)
Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score of ≤ 0, ≤ 6, and ≤ 12 points. In order to calculate time to first median placebo deterioration in DAD, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the DAD total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the DAD total score of 7 points or more and the worsening is confirmed by the DAD assessment at the next non-missing visit.
Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan)
Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score was <12.
Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78
The CDR-SOB is a global clinical staging instrument that sums 6 clinical ratings: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the Clinical Dementia Rating Scale (CDR) interview. The CDR includes discussions with the participant and caregiver using a structured format. This scale had to be administered by a trained and certified global rater who did not have access to any information regarding adverse events experienced by the participant. CDR-SOB total score range is 0 (least impairment) to 18 (most impairment); a negative change from baseline indicates an improvement.

Full Information

First Posted
May 2, 2008
Last Updated
May 3, 2016
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00676143
Brief Title
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Official Title
A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Terminated
Why Stopped
The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.
Study Start Date
January 2008 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
November 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
antibody, immunotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bapineuzumab 0.5 mg/kg
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
bapineuzumab
Other Intervention Name(s)
AAB-001
Intervention Description
Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Primary Outcome Measure Information:
Title
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78
Description
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Time Frame
Baseline and 78 weeks
Title
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78
Description
The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement.
Time Frame
Baseline and 78 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Brain Amyloid Burden at Week 71
Description
Brain amyloid burden as imaged by 11C-Pittsburgh compound B (PIB) positron emission tomography (PET). The latter is a semi-quantitative measure of the extent of fibrillar amyloid in the brain. PIB PET measurements were made in cortical regions found to have the highest burden of fibrillar amyloid at autopsy in participants diagnosed as having Alzheimer's pathology, and also regions reported to have the highest average retention of PIB signal in previous PET studies enrolling participants with probable AD. This parameter reflects overall brain amyloid deposition as indexed by imaging. The change from baseline was measured as average standard uptake value ratio (SUVr) in prespecified regions of interest (ROI) assessed by PIB PET imaging in a subset of participants.
Time Frame
Baseline and 71 weeks
Title
Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71
Description
Biomarkers CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. An elevation in levels of tau, as well as specific p-tau species, is thought to be a marker for progressive cellular degeneration in AD. Accordingly, a reduction from baseline in levels of CSF tau in participants who received bapineuzumab compared with participants who received placebo may be indicative of a reduction in neuronal loss in participants treated with bapineuzumab.
Time Frame
Baseline and 71 Weeks
Title
Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71
Description
Cerebral atrophy correlates closely with the gradual cognitive decline in AD and can be visualized by MRI. The BBSI technique involves positional matching of serial 3-dimensional MRI brain images, such that brain MRI-image volumes were first registered and then subtracted from each other. Atrophy rates would generally be expected to be lower if the underlying disease was attenuated by effective treatment.
Time Frame
Baseline and 71 Weeks
Title
Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78
Description
Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. ADAS-Cog/11 total score range is 0 (least impairment) to 70 (most impairment); a negative treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Time Frame
Week 39 to Week 78
Title
Divergence of Effect on the DAD Total Scores From Week 39 to Week 78
Description
Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. DAD total score range is 0 to 100; a positive treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Time Frame
Week 39 to Week 78
Title
Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)
Description
The time to first median placebo deterioration, defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score greater than or equal to the median worsening observed at Week 78 in the placebo group. The Kaplan Meier estimate of median time to first median placebo deterioration was presented.
Time Frame
Baseline and 78 Weeks
Title
Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)
Description
The time to first clinically meaningful deterioration was defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score of >=7.
Time Frame
Baseline and 78 Weeks
Title
Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan)
Description
The time to first median placebo deterioration was defined as the first time a participant experienced a decrease (worsening) in DAD total score greater than or equal to the median worsening at Week 78 in the placebo group.
Time Frame
Baseline and 78 Weeks
Title
Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis)
Description
The time to first clinically meaningful deterioration was defined as the first time a participant experienced a decrease (worsening) from baseline in DAD total score of >=12.
Time Frame
Baseline and 78 Weeks
Title
Change From Baseline in Dependence Scale Total Score at Week 78
Description
The Dependence Scale (DS) is a 13-item, caregiver-rated instrument for determining the amount of support required by a participant with AD. The DS total score ranges from 0 to 15, with higher scores indicating more need for assistance. The DS was administered as an interview to the caregiver at scheduled study visits.
Time Frame
Baseline and 78 Weeks
Title
Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan)
Description
Percentage of participants with worsening from baseline to Week 78 in ADAS-Cog/11 total score of ≤0, ≤3, and ≤7 points were reported. In order to calculate time to first median placebo deterioration in ADAS-Cog/11, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the ADAS-Cog/11 total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the ADAS-Cog/11 total score of 7 points or more and the worsening is confirmed by the ADAS-Cog/11 assessment at the next non-missing visit.
Time Frame
Baseline and 78 Weeks
Title
Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)
Description
Percentage of participants whose increase (worsening) from baseline to Week 78 in ADAS-Cog/11 total score was <7.
Time Frame
Baseline and 78 Weeks
Title
Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan)
Description
Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score of ≤ 0, ≤ 6, and ≤ 12 points. In order to calculate time to first median placebo deterioration in DAD, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the DAD total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the DAD total score of 7 points or more and the worsening is confirmed by the DAD assessment at the next non-missing visit.
Time Frame
Baseline and 78 Weeks
Title
Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan)
Description
Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score was <12.
Time Frame
Baseline and 78 Weeks
Title
Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78
Description
The CDR-SOB is a global clinical staging instrument that sums 6 clinical ratings: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the Clinical Dementia Rating Scale (CDR) interview. The CDR includes discussions with the participant and caregiver using a structured format. This scale had to be administered by a trained and certified global rater who did not have access to any information regarding adverse events experienced by the participant. CDR-SOB total score range is 0 (least impairment) to 18 (most impairment); a negative change from baseline indicates an improvement.
Time Frame
Baseline and 78 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
88 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD Concurrent use of cholinesterase inhibitor or memantine allowed, if stable. Caregiver will participate and be able to attend clinic visits with patient. Exclusion Criteria: Significant neurological disease other than AD, or a major psychiatric disorder Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body) Woman of childbearing potential
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Center for Psychiatric Medicine
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Participant and Clinical Interactions Resources
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
UAB Clinical Research Pharmacy-Russell Clinic
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
University of Alabama-Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Dedicated Clinical Research
City
Goodyear
State/Province
Arizona
ZIP/Postal Code
85395
Country
United States
Facility Name
Banner Alzheimer's Institute
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
Jeffrey S. Gitt, DO, PC
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85032
Country
United States
Facility Name
The Compounding Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85032
Country
United States
Facility Name
HOPE Research Institute
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85050
Country
United States
Facility Name
Clinical Trials, Inc.
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
AC Institute, Incorporated
City
Carson
State/Province
California
ZIP/Postal Code
90746
Country
United States
Facility Name
Collaborative Neuroscience Network, Inc
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
San Francisco Clinical Research Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94109
Country
United States
Facility Name
Alpine Clinical Research Center, Inc.
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80304
Country
United States
Facility Name
Associated Neurologists, PC
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80304
Country
United States
Facility Name
Mile HIgh Research Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
Associated Neurologists of Southern Connecticut, P.C.
City
Fairfield
State/Province
Connecticut
ZIP/Postal Code
06824
Country
United States
Facility Name
Bendheim Cancer Center
City
Greenwich
State/Province
Connecticut
ZIP/Postal Code
06830
Country
United States
Facility Name
Center for Healthy Aging
City
Greenwich
State/Province
Connecticut
ZIP/Postal Code
06830
Country
United States
Facility Name
Alzheimer's Disease Research Unit
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Facility Name
Hospital Research Unit
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Facility Name
Investigational Drug Service
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
Facility Name
Moshe Hasbani, MD
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
Facility Name
Norman S. Werdiger, MD
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Facility Name
MR Research Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Yale PET Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Research Center for Clinical Studies, Inc.
City
Norwalk
State/Province
Connecticut
ZIP/Postal Code
06851
Country
United States
Facility Name
JEM Research Institute, LLC
City
Atlantis
State/Province
Florida
ZIP/Postal Code
33462
Country
United States
Facility Name
JEM Research Institute
City
Atlantis
State/Province
Florida
ZIP/Postal Code
33462
Country
United States
Facility Name
Medical Specialist of the Palm Beaches
City
Atlantis
State/Province
Florida
ZIP/Postal Code
33462
Country
United States
Facility Name
Brain Matters Research
City
Delray Beach
State/Province
Florida
ZIP/Postal Code
33445
Country
United States
Facility Name
Compass Research, LLC
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Palm Beach Neurological Center
City
Palm Beach Gardens
State/Province
Florida
ZIP/Postal Code
33418
Country
United States
Facility Name
Neurostudies Inc
City
Port Charlotte
State/Province
Florida
ZIP/Postal Code
33952
Country
United States
Facility Name
Roskamp Institute
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34243
Country
United States
Facility Name
University of South Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30033
Country
United States
Facility Name
Neurostudies.net
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30033
Country
United States
Facility Name
NeuroStudies.net
City
Lawrenceville
State/Province
Georgia
ZIP/Postal Code
30045
Country
United States
Facility Name
Alexian Brothers Medical Center
City
Elk Grove Village
State/Province
Illinois
ZIP/Postal Code
60007
Country
United States
Facility Name
Southern Illinois University School of Medicine Department
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62702
Country
United States
Facility Name
Memorial Medical Center
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62781
Country
United States
Facility Name
University of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
Lake Charles Clinical Trials
City
Lake Charles
State/Province
Louisiana
ZIP/Postal Code
70629
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Massachusetts General Hosptial
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Brigham & Womens Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Boston Univeristy ADCRP
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
General Clincial Research Center (Infusion Location)
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
IDS Pharmacy (Drug Receipt). Attn:Hyesson Hong
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
Shields MRI
City
Dartmouth
State/Province
Massachusetts
ZIP/Postal Code
02747
Country
United States
Facility Name
Neuroscience Research of the Berkshires
City
Pittsfield
State/Province
Massachusetts
ZIP/Postal Code
01201
Country
United States
Facility Name
Springfield Neurology Associates, LLC
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01104
Country
United States
Facility Name
University of Michigan Health System
City
Ann Arbor,
State/Province
Michigan
ZIP/Postal Code
48109-5872
Country
United States
Facility Name
University of Michigan Hospital and Health System
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48105-2945
Country
United States
Facility Name
University of Michigan Health System
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
University of Michigan Health System
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48110
Country
United States
Facility Name
Michigan State University
City
East Lansing
State/Province
Michigan
ZIP/Postal Code
48824
Country
United States
Facility Name
Hattiesburg Clinic
City
Hattiesburg
State/Province
Mississippi
ZIP/Postal Code
39401
Country
United States
Facility Name
The Center for Pharmaceutical Research P.C.
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64114
Country
United States
Facility Name
Memory Enhancement Center of America, Inc.
City
Eatontown
State/Province
New Jersey
ZIP/Postal Code
07724
Country
United States
Facility Name
Pharmcare USA
City
Edison
State/Province
New Jersey
ZIP/Postal Code
08837
Country
United States
Facility Name
Alzheimer's Research Corp./Merician Institute for Aging
City
Manchester
State/Province
New Jersey
ZIP/Postal Code
08759
Country
United States
Facility Name
Neurological Care of Central New York
City
Liverpool
State/Province
New York
ZIP/Postal Code
13088
Country
United States
Facility Name
Carolina Neuropsychological Services, Inc
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Healthsouth Blue Ridge Surgery Center
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Raleigh Neurology Associates
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Wake Radiology Associates
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Ohio State University Imaging@Martha Moorehouse
City
Columbs
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
The Ohio State University
City
Columbs
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
The Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
Summit Research Network(Oregon) Inc.
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
Facility Name
Providence Brain Institute
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Providence Cognitive Assessment Clinic
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Providence St. Vincent Medical Center
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Dr. Michael Gabe (Clinic)
City
Silverton
State/Province
Oregon
ZIP/Postal Code
97381
Country
United States
Facility Name
Abington Memorial Hosptial
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Facility Name
Abington Neurological Associates
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Facility Name
Abington Neurological Assoc
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Facility Name
Andorra MRI of Flourtown
City
Flourtown
State/Province
Pennsylvania
ZIP/Postal Code
19031
Country
United States
Facility Name
The Clinical Trial Center, LLC
City
Jenkintown
State/Province
Pennsylvania
ZIP/Postal Code
19046
Country
United States
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Investigational New Drug Services
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
University of Pennsylvania-Penn Memory Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
UPENN Clinical and Transitional Research Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Jefferson Hospital for Neuroscience
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Thomas Jefferson University Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Abington Neurological Associates
City
Willow Grove
State/Province
Pennsylvania
ZIP/Postal Code
19090
Country
United States
Facility Name
Rhode Island Mood and Memory Research Institute
City
East Providence
State/Province
Rhode Island
ZIP/Postal Code
02914
Country
United States
Facility Name
Simpson's Pharmacy
City
Pawtucket
State/Province
Rhode Island
ZIP/Postal Code
02861
Country
United States
Facility Name
Butler Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02906
Country
United States
Facility Name
Medical University of South Carolina Hospitals and Clinics
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
MUSC
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Medical University of South Carolina
City
North Charleston
State/Province
South Carolina
ZIP/Postal Code
29406
Country
United States
Facility Name
Texas Neurology, P.A.
City
Dallas
State/Province
Texas
ZIP/Postal Code
75214
Country
United States
Facility Name
Innovative Clinical Trials
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Integra Clinical Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Integra Clinical Research, LLC
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
Integra Clinical Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
Vista Infusions
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
Inventive Infusion Solutions
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
Inventive Infusions Solutions
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
The Memory Clinic
City
Bennington
State/Province
Vermont
ZIP/Postal Code
05201
Country
United States
Facility Name
The Pharmacy
City
Bennington
State/Province
Vermont
ZIP/Postal Code
05201
Country
United States
Facility Name
Waisman Center (PET only)
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705-2280
Country
United States
Facility Name
University of Wisconsin School of Medicine and Public Health
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705
Country
United States
Facility Name
Wm S. Middleton Memorial Veterans Hospital
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705
Country
United States
Facility Name
University of Wisconsin Hospitals and Clinics
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
Facility Name
University of Wisconsin School of Medicine and Public Health
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
Facility Name
Instituto Medico Congreso
City
Buenos Aires
ZIP/Postal Code
1090
Country
Argentina
Facility Name
Cemic University Hospital
City
Buenos Aires
ZIP/Postal Code
1431
Country
Argentina
Facility Name
Hospital Italiano de Buenos Aires
City
Buenos Aires
ZIP/Postal Code
C1199ABD
Country
Argentina
Facility Name
Instituto Kremer
City
Cordoba
ZIP/Postal Code
5004
Country
Argentina
Facility Name
Gosford Hospital; Pharmacy Dept
City
Gosford
State/Province
New South Wales
ZIP/Postal Code
2250
Country
Australia
Facility Name
Gosford Hospital
City
Gosford
State/Province
New South Wales
ZIP/Postal Code
2250
Country
Australia
Facility Name
Hornsby Kuringai Hospital
City
Hornsby
State/Province
New South Wales
ZIP/Postal Code
2077
Country
Australia
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
The Queen Elizabeth Hospital
City
Woodville South
State/Province
South Australia
ZIP/Postal Code
5011
Country
Australia
Facility Name
CDAMS Ballarat Base Hospital
City
Ballarat
State/Province
Victoria
ZIP/Postal Code
3353
Country
Australia
Facility Name
Heidelberg Repatriation Hospital
City
West Heidelberg
State/Province
Victoria
ZIP/Postal Code
3081
Country
Australia
Facility Name
Hollywood Hospital; Pharmacy Dept
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
McCusker Alzheimer's Research Foundation, Inc.
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
Medizinische Universitaet Graz
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Landeskrankenhaus Klagenfurt
City
Klagenfurt
ZIP/Postal Code
A-9020
Country
Austria
Facility Name
Allg. Krankenhaus der Stadt Wien
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
SZ Sued - Kaiser-Franz-Josef-Spital
City
Wien
ZIP/Postal Code
1220
Country
Austria
Facility Name
Donauspital
City
Wien
ZIP/Postal Code
A-1220
Country
Austria
Facility Name
ZNA Middelheim
City
Antwerpen
ZIP/Postal Code
2020
Country
Belgium
Facility Name
Az. St. Jan Ruddershove 35
City
Brugge
ZIP/Postal Code
8000
Country
Belgium
Facility Name
Cliniques Universitaires St Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Universitair Ziekenhuis Antwerpen
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Facility Name
Universitair Ziekenhuis Gasthuisberg
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
H.-Hartziekenhuis Roeselare-Menen
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Facility Name
Psicomedica Research Group
City
Santiago
ZIP/Postal Code
7530193
Country
Chile
Facility Name
Especialidades Medicas LyS
City
Santiago
Country
Chile
Facility Name
University Hospital Center Zagreb
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
Ita-Suomen Yliopisto
City
Kuopio
ZIP/Postal Code
FIN-70210
Country
Finland
Facility Name
University of Turku / CRST
City
Turku
ZIP/Postal Code
20520
Country
Finland
Facility Name
CHU Pellegrin
City
Bordeaux Cedex
ZIP/Postal Code
33076
Country
France
Facility Name
Hopital neurologique du Pr A. Vighetto
City
Bron
ZIP/Postal Code
69677
Country
France
Facility Name
Centre d'Imagerie medicale de Basse Normandie
City
Caen
ZIP/Postal Code
14000
Country
France
Facility Name
CHU de Caen
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
Hôpitaux Civils de Colmar
City
Colmar
ZIP/Postal Code
68024
Country
France
Facility Name
CHU de Dijon
City
Dijon
ZIP/Postal Code
21033
Country
France
Facility Name
CHRU de Lille
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Hôpital la Timone
City
Marseille
ZIP/Postal Code
13385
Country
France
Facility Name
CHU Hôpital Gui de Chaulliac
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
CHU Nord - Hôpital Guillaume et René Laënnec
City
Nantes - Saint Herblain
ZIP/Postal Code
44093
Country
France
Facility Name
Hôpital Cimiez C.M.R.R.
City
Nice
ZIP/Postal Code
06000
Country
France
Facility Name
Service d'Imagerie Medicale
City
Nice
ZIP/Postal Code
06002
Country
France
Facility Name
Groupe Hospitalier Broca-La Rochefoucauld
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Name
Hôpital Pitié-Salpétrière
City
Paris
ZIP/Postal Code
75651
Country
France
Facility Name
Hospital Jean Bernard CIC
City
Poitiers
ZIP/Postal Code
86000
Country
France
Facility Name
C.H.U de Reims
City
Reims
ZIP/Postal Code
51092
Country
France
Facility Name
CHU de Rennes
City
Rennes Cedex
ZIP/Postal Code
35064
Country
France
Facility Name
CHU - Hopital Charles Nicolle
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
Hôpital Purpan
City
Toulouse
ZIP/Postal Code
31059
Country
France
Facility Name
CHU Toulouse - Site Casselardit
City
Toulouse
ZIP/Postal Code
31300
Country
France
Facility Name
Charite-Universitätsmedizin Berlin
City
Berlin
ZIP/Postal Code
14050
Country
Germany
Facility Name
St. Josef-Klinikum
City
Bochum
ZIP/Postal Code
44791
Country
Germany
Facility Name
Universitaetsklinikum Dresden
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Klinikum der Albert-Ludwigs-Universitaet Freiburg
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Ortenau Klinikum Offenburg
City
Offenburg
ZIP/Postal Code
77654
Country
Germany
Facility Name
Universitaetsklinikum Ulm
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
A.O. Umberto I
City
Ancona
ZIP/Postal Code
60020
Country
Italy
Facility Name
Sezione di Neurologia - Dipartimento di Neuroscienze
City
Ancona
ZIP/Postal Code
60020
Country
Italy
Facility Name
Clinica Neurologica - II Neurologia
City
Brescia
ZIP/Postal Code
25123
Country
Italy
Facility Name
Dipartimento di Neuroscienze,
City
Catania
ZIP/Postal Code
95123
Country
Italy
Facility Name
Unita' Operativa Complessa di Neurologia
City
Catania
ZIP/Postal Code
95126
Country
Italy
Facility Name
CeSI (Centro di Scienze dell'invecchiamento) -
City
Chieti
ZIP/Postal Code
66013
Country
Italy
Facility Name
Fondazione IRCCS- Istituto Neurologico Carlo Besta
City
Milano
ZIP/Postal Code
20133
Country
Italy
Facility Name
Ospedale S. Gerardo
City
Monza
ZIP/Postal Code
20052
Country
Italy
Facility Name
Clinica Neurologica
City
Roma
ZIP/Postal Code
00128
Country
Italy
Facility Name
Unita' Operativa C - Riabilitazione Neurologica
City
Roma
ZIP/Postal Code
00179
Country
Italy
Facility Name
Universita degli Studi di Siena
City
Siena
ZIP/Postal Code
53100
Country
Italy
Facility Name
Nagoya City University Hospital
City
Nagoya
State/Province
Aichi,
ZIP/Postal Code
467-8602
Country
Japan
Facility Name
National Hospital Organization Tokyo National Hospital
City
Kiyose
State/Province
Tokyo
ZIP/Postal Code
204-8585
Country
Japan
Facility Name
Yachiyo Hospital
City
Aichi
ZIP/Postal Code
446-8510
Country
Japan
Facility Name
Kashiwado Hospital
City
Chiba
ZIP/Postal Code
260-8656
Country
Japan
Facility Name
National Hospital Organization Chiba-East Hospital
City
Chiba
ZIP/Postal Code
260-8712
Country
Japan
Facility Name
Nippon Medical School Chiba Hokusoh Hospital
City
Chiba
ZIP/Postal Code
270-1694
Country
Japan
Facility Name
National Hospital Organization Kokura Medical Center
City
Fukuoka
ZIP/Postal Code
802-8533
Country
Japan
Facility Name
Maebashi Red Cross Hospital
City
Gunma
ZIP/Postal Code
371-0014
Country
Japan
Facility Name
Gunma University Hospital
City
Gunma
ZIP/Postal Code
371-8511
Country
Japan
Facility Name
Shinozuka Hospital
City
Gunma
ZIP/Postal Code
375-0017
Country
Japan
Facility Name
National Hospital Organization Hiroshima-nishi Medical Ctr.
City
Hiroshima
ZIP/Postal Code
739-0696
Country
Japan
Facility Name
Kobe University Hospital
City
Hyogo
ZIP/Postal Code
650-0017
Country
Japan
Facility Name
Nishi-Kobe Medical Center
City
Hyogo
ZIP/Postal Code
651-2273
Country
Japan
Facility Name
Kobe City Hospital Org Kobe City Medical Cente West Hp
City
Hyogo
ZIP/Postal Code
653-0013
Country
Japan
Facility Name
Iwate Medical University Hospital
City
Iwate
ZIP/Postal Code
020-8505
Country
Japan
Facility Name
Kagawa University Hospital
City
Kagawa
ZIP/Postal Code
761-0793
Country
Japan
Facility Name
Nippon Medical School Musashi Kosugi Hospital
City
Kanagawa
ZIP/Postal Code
211-8533
Country
Japan
Facility Name
Yokohama City University Medical Center
City
Kanagawa
ZIP/Postal Code
232-0024
Country
Japan
Facility Name
Shonan Atsugi Hospital
City
Kanagawa
ZIP/Postal Code
243-8551
Country
Japan
Facility Name
Rakuwakai Otowa Hospital
City
Kyoto
ZIP/Postal Code
607-8062
Country
Japan
Facility Name
National Hospital Organization Minami-Kyoto Hospital
City
Kyoto
ZIP/Postal Code
610-0113
Country
Japan
Facility Name
National Hospital Organization Maizuru Medical Center
City
Kyoto
ZIP/Postal Code
625-8502
Country
Japan
Facility Name
National Hospital Organization Matsumoto Medical Center
City
Nagano
ZIP/Postal Code
399-0021
Country
Japan
Facility Name
National Hospital Organization Niigata National Hospital
City
Niigata
ZIP/Postal Code
945-8585
Country
Japan
Facility Name
Okayama University Hospital
City
Okayama
ZIP/Postal Code
700-8558
Country
Japan
Facility Name
National Hospital Organization Minami-Okayama Medical Center
City
Okayama
ZIP/Postal Code
701-0304
Country
Japan
Facility Name
Osaka City University Hospital
City
Osaka
ZIP/Postal Code
545-8586
Country
Japan
Facility Name
Osaka University Hospital
City
Osaka
ZIP/Postal Code
565-0871
Country
Japan
Facility Name
Kansai Medical University Takii Hospital
City
Osaka
ZIP/Postal Code
570-8507
Country
Japan
Facility Name
National HP.Org.Shizuoka Inst.Epilepsy,Neurological Disorder
City
Shizuoka
ZIP/Postal Code
420-8688
Country
Japan
Facility Name
Juntendo University Hospital
City
Tokyo
ZIP/Postal Code
113-8431
Country
Japan
Facility Name
Juntendo Tokyo Koto Geriatric Medical Center
City
Tokyo
ZIP/Postal Code
136-0075
Country
Japan
Facility Name
Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp
City
Tokyo
ZIP/Postal Code
145-0065
Country
Japan
Facility Name
Tokyo Medical University Hospital
City
Tokyo
ZIP/Postal Code
160-0023
Country
Japan
Facility Name
Tokyo Medical University Hachioji Medical Center
City
Tokyo
ZIP/Postal Code
193-0998
Country
Japan
Facility Name
OCA Hospital
City
Monterrey
State/Province
Nuevo León
ZIP/Postal Code
64000
Country
Mexico
Facility Name
Instituto Biomedico de Investigacion A.C
City
Aguascalientes
ZIP/Postal Code
20127
Country
Mexico
Facility Name
Amphia Ziekenhuis
City
Breda
State/Province
Noord Brabant
ZIP/Postal Code
4818 CK
Country
Netherlands
Facility Name
Tergooi Ziekenhuizen
City
Hilversum
State/Province
Noord Holland
ZIP/Postal Code
1213 XZ
Country
Netherlands
Facility Name
Kennemer Gasthuis
City
Haarlem
State/Province
The Netherlands
ZIP/Postal Code
2035 RC
Country
Netherlands
Facility Name
Jeroen Bosch Ziekenhuis
City
's-Hertogenbosch
ZIP/Postal Code
5223 GZ
Country
Netherlands
Facility Name
Medisch Centrum Alkmaar
City
Alkmaar
ZIP/Postal Code
1815 JD
Country
Netherlands
Facility Name
Vrije Universiteit Medisch Centrum
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands
Facility Name
Catharina Ziekenhuis
City
Eindhoven
ZIP/Postal Code
5623 EJ
Country
Netherlands
Facility Name
Medisch Centrum Leeuwarden
City
Leeuwarden
ZIP/Postal Code
8934 AD
Country
Netherlands
Facility Name
Erasmus MC
City
Rotterdam
ZIP/Postal Code
3015 CE
Country
Netherlands
Facility Name
The Memory Clinic
City
Auckland
State/Province
NZ
ZIP/Postal Code
0622
Country
New Zealand
Facility Name
Signet Research
City
Christchurch
ZIP/Postal Code
8014
Country
New Zealand
Facility Name
NZOZ Dom Suer Ryder, Pallmed Sp. z o.o.
City
Bydgoszcz
ZIP/Postal Code
85-796
Country
Poland
Facility Name
Szpital Uniwersytecki, Oddzial Kliniczny Klinik Chorob Wewnetrznych i
City
Krakow
ZIP/Postal Code
31-531
Country
Poland
Facility Name
NZOZ "NEURO-KARD" "ILKOWSKI I PARTNERZY" Spolka Partnerska Lekarzy
City
Poznan
ZIP/Postal Code
61-289
Country
Poland
Facility Name
Oddzial Neurologiczny i Udarowy Szpital Wolski im. dr Anny Gostynskiej,
City
Warszawa
ZIP/Postal Code
01-211
Country
Poland
Facility Name
Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika
City
Warszawa
ZIP/Postal Code
02-097
Country
Poland
Facility Name
Hospital Fernando da Fonseca
City
Amadora
ZIP/Postal Code
2720-276
Country
Portugal
Facility Name
Hospitais Da Universidade De Coimbra
City
Coimbra
ZIP/Postal Code
3000-075
Country
Portugal
Facility Name
Hospital Santa Maria
City
Lisboa
ZIP/Postal Code
1649-028
Country
Portugal
Facility Name
Klinicki centar Srbije
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Clinical Centre Kragujevac, Clinic of Psichiatry
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Facility Name
Klinicki Centar Vojvodina
City
Novi Sad
ZIP/Postal Code
21000
Country
Serbia
Facility Name
Diagnostic Imaging Center
City
Sremska Kamenica
ZIP/Postal Code
21204
Country
Serbia
Facility Name
Institute for Cardiovascular Diseases of Vojvodina
City
Sremska Kamenica
ZIP/Postal Code
21204
Country
Serbia
Facility Name
Psychiatricka ambulancia
City
Bratislava
ZIP/Postal Code
820 07
Country
Slovakia
Facility Name
Univerzitna nemocnica Bratislava
City
Bratislava
ZIP/Postal Code
825 56
Country
Slovakia
Facility Name
Psychiatricka nemocnica Michalovce, n.o.
City
Michalovce
ZIP/Postal Code
071 01
Country
Slovakia
Facility Name
Vseobecna nemocnica Rimavska Sobota
City
Rimavska Sobota
ZIP/Postal Code
979 12
Country
Slovakia
Facility Name
Boithuso Caregivers
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1709
Country
South Africa
Facility Name
The Osteoporosis and Memory Centre
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2196
Country
South Africa
Facility Name
Denmar Clinic
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0081
Country
South Africa
Facility Name
St Augustine's Medical Centre 2
City
Durban
State/Province
Kwa Zulu Natal
ZIP/Postal Code
4001
Country
South Africa
Facility Name
Flexivest Fourteen Research Center
City
Bellville
State/Province
Western Cape
ZIP/Postal Code
7530
Country
South Africa
Facility Name
Panorama Psychiatry and Memory Clinic
City
Panorama
State/Province
Western Cape
ZIP/Postal Code
7500
Country
South Africa
Facility Name
Hospital General Universitario de Elche
City
Elche
State/Province
Alicante
ZIP/Postal Code
03203
Country
Spain
Facility Name
Hospital Mutua de Terrassa
City
Terrassa
State/Province
Barcelona
ZIP/Postal Code
08221
Country
Spain
Facility Name
Hospital Virgen del Puerto
City
Plasencia
State/Province
Caceres
ZIP/Postal Code
10600
Country
Spain
Facility Name
Hospital Universitario Son Espases
City
Palma de Mallorca
State/Province
Islas Baleares
ZIP/Postal Code
07010
Country
Spain
Facility Name
CLONUS
City
Palma de Mallorca
State/Province
Islas Baleares
ZIP/Postal Code
07014
Country
Spain
Facility Name
Hospital de Donostia
City
San Sebastian
State/Province
Pais Vasco
ZIP/Postal Code
20014
Country
Spain
Facility Name
Hospital de Cruces
City
Baracaldo
State/Province
Vizcalla
ZIP/Postal Code
48903
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Fundacio ACE Institut Catala de Neurociences Aplicades
City
Barcelona
ZIP/Postal Code
08014
Country
Spain
Facility Name
Centro Internacional de Medicina Avanzda (CIMA)
City
Barcelona
ZIP/Postal Code
08034
Country
Spain
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Facility Name
Hospital Divino Valles
City
Burgos
ZIP/Postal Code
09006
Country
Spain
Facility Name
Hospital de la Princesa
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Facility Name
Hospital Universitario Ramon y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Hospital Clinico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Hospital Universitario Virgen de la Arrixaca
City
Murcia
ZIP/Postal Code
30120
Country
Spain
Facility Name
Malmo University Hospital
City
Malmo
ZIP/Postal Code
21 224
Country
Sweden
Facility Name
Uppsala Imanet AB
City
Uppsala
ZIP/Postal Code
751 09
Country
Sweden
Facility Name
Akademiska Sjukhuset
City
Uppsala
ZIP/Postal Code
75185
Country
Sweden
Facility Name
ORKI, enheten for radiologi
City
Uppsala
ZIP/Postal Code
75185
Country
Sweden
Facility Name
Memory Clinic Neuro-Psychologie Zentrum
City
Basel
State/Province
BS
ZIP/Postal Code
CH-4031
Country
Switzerland
Facility Name
Hopitaux Universitaires de Geneve
City
Les Acacias
State/Province
GE
ZIP/Postal Code
1227
Country
Switzerland
Facility Name
CHUV Lausanne
City
Lausanne
State/Province
VD
ZIP/Postal Code
1005
Country
Switzerland
Facility Name
Hopitaux Universitaires de Geneve
City
Thonex-Geneva
ZIP/Postal Code
CH-1226
Country
Switzerland
Facility Name
MAC UK Neuroscience Ltd
City
Blackpool
State/Province
Lancashire
ZIP/Postal Code
FY2 0JH
Country
United Kingdom
Facility Name
MAC UK Neuroscience, Research Assessment Centre
City
Trafford Park
State/Province
Manchester
ZIP/Postal Code
M32 0UT
Country
United Kingdom
Facility Name
Pollard Park Health Centre
City
Bradford
ZIP/Postal Code
BD3 0DQ
Country
United Kingdom
Facility Name
Clinical Investigation and Research Unit (CIRU)
City
Brighton
ZIP/Postal Code
BN2 5BE
Country
United Kingdom
Facility Name
Glasgow Memory Clinic
City
Glasgow
ZIP/Postal Code
G20 0XA
Country
United Kingdom
Facility Name
Kings College Hospital
City
London
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
Facility Name
Dept. of Neurosciences Charing Cross Hospital
City
London
ZIP/Postal Code
W6 8RF
Country
United Kingdom
Facility Name
Newcastle General Hospital
City
Newcastle upon Tyne
ZIP/Postal Code
NE4 5PL
Country
United Kingdom
Facility Name
Northampton General Hospital
City
Northampton
ZIP/Postal Code
NN1 5BD
Country
United Kingdom
Facility Name
Llandough Hospital
City
Penarth
ZIP/Postal Code
CF64 2XX
Country
United Kingdom
Facility Name
Royal Hallamshire Hospital
City
Sheffield
ZIP/Postal Code
S10 2JF
Country
United Kingdom
Facility Name
Grenoside Grange Hospital
City
Sheffield
ZIP/Postal Code
S35 8QS
Country
United Kingdom
Facility Name
Victoria Hospital
City
Swindon
ZIP/Postal Code
SN3 6BW
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
27176461
Citation
Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS; Bapineuzumab 3000 and 3001 Clinical Study Investigators. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016 May 12;8(1):18. doi: 10.1186/s13195-016-0189-7.
Results Reference
derived
PubMed Identifier
26297092
Citation
Lacey L, Bobula J, Rudell K, Alvir J, Leibman C. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed. Value Health. 2015 Jul;18(5):638-45. doi: 10.1016/j.jval.2015.03.1787. Epub 2015 Apr 10.
Results Reference
derived
Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3133K1-3001&StudyName=Study%20Evaluating%20the%20Safety%20and%20Efficacy%20of%20Bapineuzumab%20in%20Alzheimer%20Disease%20Patients
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

We'll reach out to this number within 24 hrs